Portfolio / EsoBiotec
EsoBiotec, founded in 2021, is a preclinical stage company that develops technologies to enable immune effector cell engineering inside the patient to make such cells recognize and destroy cancer cells. Thus, the complex and expensive logistics associated with current CAR T cell therapies are avoided.
With this approach, EsoBiotec aims to greatly improve access to these novel therapeutic modalities that effectively treat and even cure cancer, such as CAR-T and TCR-T cell therapies.
Company: EsoBiotec
Fund: III
Status: Active
Team member: Michel Briejer
Technology: Therapeutics
Website: esobiotec.com